Deficiency of adenosine deaminase (ADA) is the cause of an autosomal recessive form of immunodeficiency. We sought to define, at a molecular level, the mutations responsible for ADA deficiency in the cell line GM-1715, derived from an immunodeficient patient. Full-length complementary DNA (cDNA) for ADA was synthesized and cloned from the cell line. Sequence analysis of the clones revealed a point mutation in codon 101 (CGG to CAG) that predicts an amino acid change from arginine to glutamine. Southern blot analysis, based on silent polymorphisms in the cDNA sequence, indicated that only one of the defective alleles of the GM-1715 line had been sequenced. The mutation that was identified appears to be responsible for the loss of function in this allele, since the predicted primary structure of the enzyme is otherwise entirely normal.
Introduction
Deficiency of the enzyme adenosine deaminase (ADA)' (EC 3.5.4.4) is responsible for approximately one-third of the cases of recessively inherited severe combined immune deficiency (SCID) (for review see reference 1). Most SCID patients manifest combined T cell and B cell failure, though partial ADA deficiency may allow the relative sparing of humoral immunity. Structural changes in the ADA protein, rather than regulatory mutations, may be responsible for most cases of ADA deficiency, since ADA messenger RNA (mRNA) is usually detectable in cell lines from ADA-deficient patients at levels equaling or exceeding those in normal cells (2) (3) (4) . Also, structural analysis of mRNA from a number of SCID cell lines revealed abnormalities in only -10% of mRNAs examined, suggesting the presence of point mutations in the remainder (5) . So far, none of the mutations causing ADA deficiency has been precisely characterized.
We report here the sequence of ADA complementary DNA (cDNA) from a cell line (GM-1715) derived from a patient with partial ADA deficiency and impaired T cell immunity. This patient's B cell function has been reported to be normal (6) . A point mutation resulting in a nonconservative amino acid change appears to be the cause of a loss of function in one ADA allele in this patient.
Methods
The lymphoid cell line GM-1715 (Human Genetic Mutant Cell Repository, Camden, NJ) was maintained in RPMI 1640 medium supplemented with 10% fetal calf serum.
Total RNA was prepared from cells by lysis in buffer containing 6 M guanidine hydrochloride. Poly A' RNA was isolated by oligo-(dT) cellulose chromatography (7) . cDNA was synthesized by the method of Okayama and Berg (8) , as modified by Gubler and Hoffman (9), blunt-ended with T4 polymerase, and ligated to synthetic EcoRI linkers after methylation of internal EcoRI sites. After it was digested with EcoRI, cDNA was purified from free linkers by Sepharose CL4-B chromatography and ligated into EcoRI-digested alkaline phosphatasetreated lambda gtlI DNA (10) . Benton-Davis screening of the library of 375,000 phage clones was performed by standard methods (7), using as a probe a previously characterized 1.3-kilobase (kb) ADA cDNA insert (from ADA clone lb in reference 19) .
For further analysis, the inserts of positive gtl 1 clones were subcloned into the plasmid pBR 322 and then into M13 mplI (11) . A series of oligonucleotides complementary to the coding strand of the previously published human ADA cDNA sequence (2, 12) was synthesized by the modified phosphotriester method (13) , either manually or on a DNA synthesizer (model SAM I; Biosearch, San Rafael, CA). Their sequences are given in Table I and their positions along the mRNA are shown in Fig. 1 . These oligonucleotides were used for internal priming of sequencing reactions (14, 15) on the M13 subclones of ADA cDNAs from the GM-17 15 cell line. An M 13 universal primer (New England Biolabs, Beverly, MA) was used to complete the 3' ends of the sequences.
For Southern blot analysis (16), total genomic DNA was prepared from cultured cells or from normal human blood by the method of Bell et al. (17) , and after digestion and electrophoresis, transferred to GeneScreen Plus membrane (New England Nuclear, Boston, MA). DNA fragments used as probes were cut from low-melt agarose gels and labeled with large fragments of DNA polymerase I by random oligonucleotide priming (18) .
Results
For rapid sequencing of the ADA cDNAs, we adopted a strategy that is generally applicable both for the characterization of further ADA cDNAs and for the sequencing of any mutant cDNA for which the normal sequence is known. By priming 5'-TCTACAAACTCATAGGC-3' (2) at three positions. Two of these are silent polymorphisms (see Table  II ), while the remaining one, a G to A change at position 302, causes the nonconservative amino acid change arginine to glutamine (see Fig. 1 ). As no other amino acid substitutions were predicted by the cDNA sequence, we inferred that this arginine to glutamine change is responsible for the functional deficiency of this allele.
Sequencing of further cDNA clones (171 5-D, 1715-H, and 1715-L) again revealed the same three alterations in all three clones. Approximately 75% of each of these clones was sequenced. No differences were found among the four cDNA clones from GM-1715. Sequencing of the normal (and demonstrably functional) ADA cDNA (19) 
* Numbering is as in reference 5.
Comparison of the present sequences with the published sequence from our laboratory (2) The silent A to G change at position 534 in our 1715
ADA cDNA clones creates a new cleavage site for the restriction enzyme Bal I. To address the question of whether GM-1715 is homozygous for the allele whose cDNA we sequenced, Southern blot analysis of Bal I-digested genomic DNAs was performed, using as probe an internal Pst I fragment of cDNA spanning this site (see Fig. 1 ). This showed GM-1715, as well as the commonly used T cell line MOLT 4, to be heterozygous for this polymorphism (Fig. 2) .
Discussion
The mutations causing ADA deficiency are known to be heterogeneous (4, 5, 21) , but to date none has been defined at the sequence level. In most ADA-deficient cell lines, ADA A number of polymorphic sites in the ADA cDNA sequence have been noted in the present study. All but one of these can be recognized by comparison of the previously published sequences (5, 12, 20) , which differ at these positions. Polymorphisms such as that giving rise to the new Bal I restriction site in GM-1715 will distinguish between alleles and facilitate identification of cDNAs that probably differ with respect to their mutations. This work demonstrates that a structural change in the ADA sequence may cause ADA deficiency. Further sequence analysis of other mutant alleles will permit detailed mapping of sites in the ADA protein that are critical to enzyme function and stability in vivo.
